Istituto di Ricerca Sulle Acque, Consiglio Nazionale delle Ricerche, Viale De Blasio 5, 70132 Bari, Italy.
Bioresour Technol. 2011 Jul;102(13):7012-5. doi: 10.1016/j.biortech.2011.04.056. Epub 2011 Apr 23.
This paper aims to demonstrate that integrating biological process and photocatalytic oxidation in a system operated in recycling mode can be a promising technology to treat pharmaceutical wastewater characterized by simultaneous presence of biodegradable and refractory/inhibitory compounds. A lab-scale system integrating a membrane bioreactor (MBR) and a TiO(2) slurry photoreactor was fed on simulated wastewater containing 10mg/L of the refractory drug Carbamazepine (CBZ). Majority of chemical oxygen demand (COD) was removed by the MBR, while the photocatalytic oxidation was capable to degrade CBZ. CBZ degradation kinetics and its impacts on the biological process were studied. The adoption of a recycling ratio of 4:1 resulted in removal of up to 95% of CBZ. Effluent COD reduction, sludge yield increase and respirometric tests suggested that the oxidation products were mostly biodegradable and not inhibiting the microbial activity. These results evidenced the advantages of the proposed approach for treating pharmaceutical wastewater and similar industrial effluents.
本文旨在证明，将生物过程与光催化氧化集成在循环模式下运行的系统中，可能是一种很有前途的技术，可以处理同时存在可生物降解和难降解/抑制性化合物的制药废水。一个将膜生物反应器（MBR）和 TiO2浆态光反应器集成的实验室规模系统，以含有 10mg/L 难降解药物卡马西平（CBZ）的模拟废水为进料。MBR 去除了大部分化学需氧量（COD），而光催化氧化则能够降解 CBZ。研究了 CBZ 降解动力学及其对生物过程的影响。采用 4:1 的循环比，可去除高达 95%的 CBZ。出水 COD 降低、污泥产率增加和呼吸计量试验表明，氧化产物大多是可生物降解的，不会抑制微生物活性。这些结果证明了该方法在处理制药废水和类似工业废水方面的优势。
